These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30608237)

  • 1. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
    Moore S; Leung B; Wu J; Ho C
    Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.
    Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka S; Bebb DG; Cheung WY
    Am J Clin Oncol; 2019 Jan; 42(1):75-81. PubMed ID: 30211724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.
    Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Bando T; Date H
    Ann Surg Oncol; 2014 Aug; 21(8):2546-54. PubMed ID: 24633668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
    Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
    Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection.
    Lee NK; Moon SH; Kim TH; Han JY; Yun T; Kim HT; Lee HS; Kim MS; Lee JM; Cho KH; Lee JS
    Clin Lung Cancer; 2013 Jul; 14(4):399-406. PubMed ID: 23276823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
    Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
    Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy.
    Cai XW; Xu LY; Wang L; Hayman JA; Chang AC; Pickens A; Cease KB; Orringer MB; Kong FM
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1100-5. PubMed ID: 19540063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer.
    Oshiro Y; Mizumoto M; Okumura T; Hashimoto T; Fukumitsu N; Ohkawa A; Kanemoto A; Hashii H; Ohno T; Sakae T; Tsuboi K; Sakurai H
    J Thorac Oncol; 2012 Feb; 7(2):370-5. PubMed ID: 22157368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
    Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland.
    Zhu Q; Zang Q; Jiang ZM; Wang W; Cao M; Su GZ; Zhen TC; Zhang XT; Sun NB; Zhao C
    Asian Pac J Cancer Prev; 2015; 16(9):4013-8. PubMed ID: 25987078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.